SCHEMBL13629414

SCHEMBL13629414

CCc1ccc(NS(=O)(=O)c2ccc(C)cc2)cc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
HPGD P15428 1/20 0.55
ALDH1A1 P00352 6/20 0.55
LMNA P02545 3/20 0.55
THRB P10828 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
FFAR4 Q5NUL3 1/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
PTPRC P08575 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
GAA P10253 2/20 0.53
MAPK1 P28482 1/20 0.53
GFER P55789 1/20 0.53
MCL1 Q07820 1/20 0.53
TDP1 Q9NUW8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629423 0.88 CES1 (0.60) MAPTALDH1A1FFAR4GAATDP1
SCHEMBL13629552 0.85 PKM (0.74) MAPTHPGDALDH1A1LMNASMN1; SMN2
SCHEMBL13629421 0.84 BRD4 (0.56) MAPTFFAR4CA1CA2MEN1
SCHEMBL13629416 0.84 ALDH1A1 (0.60) MAPTHPGDALDH1A1LMNASMN1; SMN2
SCHEMBL14403177 0.83 PKM (0.71) MAPTALDH1A1LMNATHRBSMN1; SMN2
SCHEMBL30532923 0.83 PKM (0.71) MAPTALDH1A1LMNATHRBSMN1; SMN2
SCHEMBL13629553 0.82 PKM (0.56) MAPTALDH1A1LMNAPKM
SCHEMBL28790906 0.79 FFAR4 (0.68) MAPTHPGDALDH1A1LMNATHRB
SCHEMBL2005010 0.79 CA12 (0.81) MAPTHPGDALDH1A1LMNASMN1; SMN2
SCHEMBL13596677 0.79 UCHL1 (0.78) MAPTHPGDALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK MAPT 1353/4885HPGD 1970/4885ALDH1A1 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.